MIRA Pharmaceuticals Reveals Promising Preclinical Results for Ketamir-2

MIRA Pharmaceuticals has unveiled preclinical data indicating that its new drug, Ketamir-2, demonstrates 60% greater efficacy over gabapentin for chemotherapy-induced neuropathic pain. The findings, utilizing a paclitaxel model in mice, suggest significant potential for Ketamir-2 in pain management.

The company is set to present these results at the Pain Therapeutics Summit in Boston. Such advancements could position Ketamir-2 for FDA breakthrough therapy and fast track designations, potentially speeding up market access for this promising treatment.

MIRA plans to file an Investigational New Drug application by the end of 2024, with Phase I trials expected to commence in early 2025. This initiative includes exploring Ketamir-2's applications in diabetic neuropathy and other conditions.

Besides pain relief, Ketamir-2 is being evaluated for treating PTSD. MIRA actively seeks support to expand research, positioning Ketamir-2 as a versatile non-opioid option for various challenges.